Search clinical trials for: Non-transplant eligible myeloma patients

Total 107985 results

University of Leeds
Takeda; Cancer Research UK; Celgene

Recruiting

Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss)

Multiple Myeloma

United Kingdom
PETHEMA Foundation
Janssen, LP; Adknoma Health Research

Recruiting

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Multiple Myeloma | Non-eligible for Autologous Stem Cell Transplantation (ASCT)

Spain
PETHEMA Foundation
GlaxoSmithKline

Recruiting

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Multiple Myeloma

Spain
Medical College of Wisconsin

Recruiting

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients (VICD)

Multiple Myeloma

United States
Sanofi

Active, not recruiting

Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)

Plasma Cell Myeloma

Mexico, Sweden, Poland, France, Czechia, Greece, Taiwan, Lithuania, Portugal, Spain, Australia, Italy, New Zealand, Russian Federation, Turkey, Japan, United States, Belgium, China, Denmark, Germany
SCRI Development Innovations, LLC
Bristol-Myers Squibb

Completed

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Multiple Myeloma

United States
Bristol-Myers Squibb

Active, not recruiting

Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel (ABE-DESCART)

Multiple Myeloma

France
Mario Boccadoro

Active, not recruiting

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. (FORTE)

MULTIPLE MYELOMA (MM)

Italy
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Fondazione EMN Italy Onlus

Active, not recruiting

A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant (KRdvsRd)

Multiple Myeloma | New Diagnosis Tumor

Italy
European Myeloma Network
Sanofi; Amgen; EMN Research Italy

Active, not recruiting

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) (IsKia)

Multiple Myeloma

Czechia, Germany, Greece, Italy, Netherlands, Norway, Spain
Celgene

Completed

Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients

Multiple Myeloma

Austria
Celgene

Active, not recruiting

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Multiple Myeloma

Netherlands, Belgium, Denmark, Germany, United Kingdom, France, Norway, Spain, Austria, Ireland, Italy, Sweden
University Hospital, Toulouse
Ministry of Health, France; Janssen, LP

Completed

Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma (IFM2014-02)

Multiple Myeloma

France, Belgium
Institut Paoli-Calmettes

Unknown

Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen (HaploMUD-RIC)

Multiple Myeloma | Non Hodgkin Lymphoma | Acute Leukemia

France
Instituto de Investigacion Sanitaria La Fe
Bristol-Myers Squibb

Terminated

Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs

Venous Thromboembolism

Spain
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

Plasma Cell Myeloma

United States
Dartmouth-Hitchcock Medical Center
The Leukemia and Lymphoma Society

Completed

Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma

Myeloma | Transplant-eligible Patients

United States
M.D. Anderson Cancer Center
Novartis

Completed

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Myeloma

United States
Grupo de Estudos Multicentricos em Onco-Hematologia

Unknown

Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation (MAXDARA)

Multiple Myeloma Stage I

Brazil
Grupo de Estudos Multicentricos em Onco-Hematologia

Completed

Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation (GBRAM003r)

Multiple Myeloma | Effects of Chemotherapy
Criterium, Inc.
Amgen

Completed

A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma (11-MM-01)

Multiple Myeloma

United States
Genzyme, a Sanofi Company

Terminated

A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care

Carcinoma, Hepatocellular

United States
Janssen-Cilag Pty Ltd

Completed

A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma

Multiple Myeloma

Australia
Cigdem Sahinbas YILMAZ
Turkish Society of Hematology Myeloma Study Group

Completed

Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma

Multiple Myeloma

Turkey
Nantes University Hospital

Not yet recruiting

Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study (DELICATESSE)

Myeloma Multiple
Jules Bordet Institute
RayzeBio, Inc.

Not yet recruiting

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (AcTRESS)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Multiple Myeloma Progression

Belgium
University Hospital, Angers

Not yet recruiting

Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. (ALHERT)

Lymphoma | Leukemia | Multiple Myeloma

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
Janssen Research & Development, LLC

Not yet recruiting

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Myelofibrosis | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Hematologic Malignancy | Aplastic Anemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Bone Marrow Transplant Rejection | Acute Lymphoblastic Leukemia (ALL), Adult
Cullinan Therapeutics Inc.

Not yet recruiting

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma
Virginia Commonwealth University

Not yet recruiting

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality (REMAIN1)

Acute Myeloid Leukemia

United States
University Hospital, Toulouse
Janssen, LP; Ligue contre le cancer, France

Not yet recruiting

Real-life Management of Patients Eligible for CAR-T Cell Therapy (CARAVAGE)

Hemopathy

France
Bristol-Myers Squibb

Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy

Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Lymphocytic Leukaemia

Belgium
Adriana Rossi

Not yet recruiting

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

United States
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France; CGenetix

Not yet recruiting

Detection of Circulating Kidney DNA in Kidney Transplant Patients Facing an Episode of Graft Rejection (DART-RREGREF)

Kidney Transplant Patients Eligible for a Solid Biopsy
Emory University
National Cancer Institute (NCI); National Center for Complementary and Integrative...

Recruiting

Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation

Lymphoma | Multiple Myeloma

United States
The Christie NHS Foundation Trust
CellCentric Ltd.

Not yet recruiting

PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma (iPREFER)

Multiple Myeloma

United Kingdom
RenJi Hospital
Shanghai JMT-Bio Inc.

Not yet recruiting

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Multiple Myeloma | Bone Diseases
Copenhagen Academy for Medical Education and Simulation

Not yet recruiting

Assessing Demographic Biases in Deep Learning Model for Fetal Growth Estimation in Clinical Practice. Patients Eligible for Inclusion Are Women with a Gestational Age Between 24-42 Weeks Undergoing a Third-trimester Growth Scan. the Image Data from the Scan Are Used to Calculate Fetal Weight.

Pregnancy Complications
Cartesian Therapeutics

Recruiting

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma (DC15-MM-01)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Incyte Biosciences Italy S.r.l
Advice Pharma Group srl

Recruiting

Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

DLBCL - Diffuse Large B Cell Lymphoma

Italy
Siriraj Hospital
Faculty of Medicine Siriraj Hospital

Not yet recruiting

Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation Between in HEPA-filtered Room and Non-HEPA-filtered Room (Step down ward)

Multiple Myeloma
Janssen-Cilag Ltd.

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials (REALiTEC)

Relapsed/Refractory Multiple Myeloma (RRMM)

France, Denmark, Israel, Spain, Italy, Germany, Sweden
PETHEMA Foundation

Recruiting

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Multiple Myeloma in Relapse

Spain
Rovi Pharmaceuticals Laboratories

Recruiting

Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia (QUARTZ)

Schizophrenia

Jordan
The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France
Centro di Riferimento Oncologico - Aviano

Recruiting

Biomechanical and Metabolic Assessment Pre and Post Vertebroplasty in Multiple Myeloma Patients With Vertebral Collapse

Multiple Myeloma

Italy
Shanxi Bethune Hospital

Recruiting

Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM

Multiple Myeloma in Relapse

China
Nantes University Hospital

Not yet recruiting

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (CY-MET-RIC)

Hematologic Malignancy | Graft Versus Host Disease
FengYan Jin
Sun Yat-sen University; Shandong Cancer Hospital and Institute; Affiliated Hospital... and other collaborators

Not yet recruiting

Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma

Multiple Myeloma | First Relapse

3

Subscribe